Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 2 (2005), Issue 7 (July)

1. Positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
   Int J Clin Oncol, 10(3): 177-81. [Abstract] [Full-text]
2. Androgen receptor cytosine, adenine, guanine repeats, and haplotypes in relation to ovarian cancer risk.
   Cancer Res, 65(13): 5974-81. [Abstract] [Full-text]
3. Pharmacokinetically guided phase I trial of topotecan and etoposide phosphate in recurrent ovarian cancer.
   Br J Cancer, 93(1): 60-9. [Abstract] [Full-text]
4. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer.
   Cancer, 104(2): 305-13. [Abstract] [Full-text]
5. Addition of an aminopeptidase N-binding sequence to human endostatin improves inhibition of ovarian carcinoma growth.
   Cancer, 104(2): 321-31. [Abstract] [Full-text]
6. Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up.
   Cancer, 104(2): 314-20. [Abstract] [Full-text]
7. Discrimination between serous low malignant potential and invasive epithelial ovarian tumors using molecular profiling.
   Oncogene, 24(29): 4672-87. [Abstract] [Full-text]
8. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
   J Surg Oncol, 91(1): 67-72. [Abstract] [Full-text]
9. Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells.
   J Biol Chem, 280(28): 26233-40. [Abstract] [Full-text]
10. Lysophosphatidic acid stimulates fas ligand microvesicle release from ovarian cancer cells.
    Cancer Immunol Immunother, 54(8): 807-14. [Abstract] [Full-text]
11. Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger.
    Int J Gynecol Cancer, 15(4): 657-62. [Abstract] [Full-text]
12. Expression of the c-Met in advanced epithelial ovarian cancer and its prognostic significance.
    Int J Gynecol Cancer, 15(4): 618-23. [Abstract] [Full-text]
13. Topotecan in heavily pretreated patients with recurrent ovarian, peritoneal, and fallopian tube carcinoma.
    Int J Gynecol Cancer, 15(4): 612-7. [Abstract] [Full-text]
14. Stage IV ovarian cancer: a retrospective study on patient's management and outcome in a single institution.
    Int J Gynecol Cancer, 15(4): 606-11. [Abstract] [Full-text]
15. Outcome of patients with early ovarian cancer undergoing three courses of adjuvant chemotherapy following complete surgical staging.
    Int J Gynecol Cancer, 15(4): 601-5. [Abstract] [Full-text]
16. Multi-institutional phase 2 study of TLK286 (TELCYTA, a glutathione S-transferase P1-1 activated glutathione analog prodrug) in patients with platinum and paclitaxel refractory or resistant ovarian cancer.
    Int J Gynecol Cancer, 15(4): 593-600. [Abstract] [Full-text]
17. Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis.
    Hum Pathol, 36(6): 605-19. [Abstract] [Full-text]
18. Menopausal hormones and risk of ovarian cancer.
    Am J Obstet Gynecol, 193(1): 76-82. [Abstract] [Full-text]
19. Yolk sac tumor in a young girl: a case report.
    Gynecol Endocrinol, 20(6): 334-5. [Abstract] [Full-text]
20. Expression of the endothelial cell differentiation gene 7 (EDG-7), a lysophosphatidic acid receptor, in ovarian tumor.
    J Obstet Gynaecol Res, 31(4): 344-51. [Abstract] [Full-text]
21. Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-overexpressing cancer cells with pyropheophorbide-a immunoconjugates.
    Cancer Res, 65(14): 6371-9. [Abstract] [Full-text]
22. SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.
    Int J Cancer, 116(4): 547-54. [Abstract] [Full-text]
23. Consolidation and maintenance treatments for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy: a review of the literature.
    Crit Rev Oncol Hematol, 55(2): 153-66. [Abstract] [Full-text]
24. Comparative gene expression analysis of ovarian carcinoma and normal ovarian epithelium by serial analysis of gene expression.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1717-23. [Abstract] [Full-text]
25. Intravaginal high-dose-rate brachytherapy for stage I endometrial cancer: a randomized study of two dose-per-fraction levels.
    Int J Radiat Oncol Biol Phys, 62(5): 1385-9. [Abstract] [Full-text]
26. Calcitonin gene polymorphism CALCA-624 (T/C) and ovarian cancer.
    Environ Mol Mutagen, 46(1): 53-8. [Abstract] [Full-text]
27. Effect of chemotherapy on circulating gastrointestinal hormone levels in ovarian cancer patients: relationship to nausea and vomiting.
    Scand J Gastroenterol, 40(6): 654-61. [Abstract] [Full-text]
28. Late ovarian relapse of TEL/AML1 positive ALL confirming that TEL deletion is a secondary event in leukemogenesis.
    Leuk Res, 29(9): 1089-94. [Abstract] [Full-text]
29. Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma.
    Gynecol Oncol, 98(2): 242-8. [Abstract] [Full-text]
30. The role of cytoreductive surgery in nongenital cancers metastatic to the ovaries.
    Gynecol Oncol, 98(2): 235-41. [Abstract] [Full-text]
31. Body weight and body mass index and ovarian cancer risk: a case-control study in China.
    Gynecol Oncol, 98(2): 228-34. [Abstract] [Full-text]
32. Successful carboplatin desensitization in patients with proven carboplatin allergy.
    Cancer, 104(3): 640-3. [Abstract] [Full-text]
33. Breastfeeding and the risk of epithelial ovarian cancer in an Italian population.
    Gynecol Oncol, 98(2): 304-8. [Abstract] [Full-text]
34. Gemcitabine and liposomal doxorubicin in the salvage treatment of ovarian cancer: updated results and long-term survival.
    Gynecol Oncol, 98(2): 267-73. [Abstract] [Full-text]
35. Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer.
    Gynecol Oncol, 98(2): 274-80. [Abstract] [Full-text]
36. Fertility-sparing surgery for ovarian low malignant potential tumors.
    Gynecol Oncol, 98(2): 263-6. [Abstract] [Full-text]
37. Meigs syndrome and gliomatosis peritonei: a case report and review of literature.
    Gynecol Oncol, 98(2): 313-7. [Abstract] [Full-text]
38. Clinicopathologic review of malignant polyps in stage 1A carcinoma of the endometrium.
    Gynecol Oncol, 98(2): 254-62. [Abstract] [Full-text]
39. In vitro model of normal, immortalized ovarian surface epithelial and ovarian cancer cells for chemoprevention of ovarian cancer.
    Gynecol Oncol, 98(2): 182-92. [Abstract] [Full-text]
40. Neoadjuvant chemotherapy for epithelial ovarian cancer--role of apoptosis.
    Cancer Chemother Pharmacol, 56(4): 427-35. [Abstract] [Full-text]
41. Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.
    Oncogene, 24(32): 5089-100. [Abstract] [Full-text]
42. BRCA1 in breast and ovarian cancer predisposition.
    Cancer Lett, 227(1): 1-7. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.